a2 Milk stock closed at NZ$8.54 after the market absorbed a set of earnings that looked solid on paper yet still demand a closer look. The immediate price action reflects a company that has already enjoyed a 24.7% gain over the past three months, so expectations were not low coming into this result.
The headline this time is not revenue growth or special dividends. It is the squeeze on profitability. Trailing net margin sits at 10.1% compared with 11.3% a year earlier, while the P/E multiple of 29.9x still leans rich versus peers. Short term traders see the move today. Long term holders will focus on whether that margin pressure eases.
Is a2 Milk trading at a genuine discount, or is it simply carrying an expensive P/E multiple that the current 10.1% net margin cannot fully support? Compare the market price and growth profile against our valuation analysis for a2 Milk.
FY 2026 Earnings Summary
- Total Revenue FY 2026 TTM vs. FY 2025 TTM: NZ$2,056.426m vs. NZ$1,899.273m (up about 8.3%)
- Net Income from Continuing Operations FY 2026 TTM vs. FY 2025 TTM: NZ$201.733m vs. NZ$192.091m (up about 5.0%)
- Basic EPS FY 2026 TTM vs. FY 2025 TTM: NZ$0.286477 per share vs. NZ$0.280295 per share (up about 2.2%)
- Trailing Net Profit Margin FY 2026 vs. Prior Year: 10.1% vs. 11.3% (margin compressed by about 1.2 percentage points)
Prefer clean charts instead of another wall of earnings tables and ratios? Get a full visual view of a2 Milk, including how its valuation compares, in our company report for a2 Milk.
a2 Milk’s Growth Story Meets Margin Reality
Bulls argue that a2 Milk can turn its product and geographic expansion into sustained, higher quality earnings. The latest result partly backs that view. Revenue reached NZ$1.97b with underlying EBITDA and NPAT both higher, which suggests the company is adding scale rather than chasing growth at any price. English label infant formula grew strongly and now includes a2 Genesis, while other nutritionals and liquid milk in Australia and the US are contributing more meaningfully. These are clear milestones for the diversification part of the thesis.
The more ambitious claim is that insourcing at Pokeno and China registration wins will lift group margins over time. Here, the evidence is mixed. Pokeno losses still drag on gross margin and China label infant formula fell sharply after supply disruption. Underlying profitability excluding Pokeno improved, but the margin uplift from vertical integration is not yet showing through at group level.
Reveal where the surface looks calm, but the multi year models start to disagree on a2 Milk’s path from here. Access the analyst estimates for a2 Milk.a2 Milk Bears Focus on Margins and China Setbacks
The bearish view on a2 Milk is that China headwinds, tougher competition and execution risk around Pokeno will cap earnings quality even if revenue grows. This result gives that argument some traction. China label infant formula fell 14% for FY26 with a 33% drop in the second half after the supply disruption. Market share in that channel slipped and offtake is currently only about 40% of the previous run rate. That is a clear milestone missed for a business with meaningful China exposure.
Bears also worry that supply chain transition could weigh on margins. Reported EBITDA declined about 2.5% to NZ$284m and site losses at a2 Pokeno pulled down gross margin, even though underlying EBITDA excluding Pokeno rose. Management still refers to future breakeven at Pokeno and to recovery through FY27. For now, the printed margin compression and China label setback keep the risk side of the story very visible.
With valuation multiples already elevated and margins under pressure, the real question for a2 Milk is whether its balance sheet, cash generation and liquidity can comfortably support the current P/E. Check the full financial health analysis of a2 Milk stockStay Ahead With Simply Wall St
If the margin squeeze and China setbacks around a2 Milk have your attention, register for free with Simply Wall St and add it to a Watchlist so you can track price against fair value and wait for a potential entry point. Once you hold the stock, use the Portfolio Command Center to cut through noise and focus on the key developments that matter for your investment thesis. For a longer term view, tap into crowd insights and different angles through the Community to stress test your thinking. By spotting potential catalysts and risks early, you may be able to act with greater confidence and stay ahead of the market.
Seeking Alternatives Beyond a2 Milk
Markets move fast and the stocks with real breakout potential rarely stay under the radar for long. Scan these fresh ideas before the momentum gets fully caught and act now.
- Target resilient compounding potential by reviewing hand picked businesses on the list of solid balance sheet and fundamentals stocks (437 results) while the market is still pricing in yesterday's information.
- Catch income opportunities before yields get compressed by tracking companies in the 432 dividend fortresses while their payouts and balance sheets remain under the radar for now.
- Ride the structural shift toward electrification by scanning producers in the 9 top copper producer stocks before the crowd fully prices in long term demand themes.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com